255 related articles for article (PubMed ID: 26564103)
1. Cytosolic Receptor Melanoma Differentiation-Associated Protein 5 Mediates Preconditioning-Induced Neuroprotection Against Cerebral Ischemic Injury.
Gesuete R; Christensen SN; Bahjat FR; Packard AE; Stevens SL; Liu M; Salazar AM; Stenzel-Poore MP
Stroke; 2016 Jan; 47(1):262-6. PubMed ID: 26564103
[TBL] [Abstract][Full Text] [Related]
2. Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling.
Gesuete R; Packard AE; Vartanian KB; Conrad VK; Stevens SL; Bahjat FR; Yang T; Stenzel-Poore MP
J Neurochem; 2012 Nov; 123 Suppl 2(Suppl 2):75-85. PubMed ID: 23050645
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism.
Leung PY; Stevens SL; Packard AE; Lessov NS; Yang T; Conrad VK; van den Dungen NN; Simon RP; Stenzel-Poore MP
Stroke; 2012 May; 43(5):1383-9. PubMed ID: 22403050
[TBL] [Abstract][Full Text] [Related]
4. Viral RNA induces type I interferon-dependent cytokine release and cell death in mesangial cells via melanoma-differentiation-associated gene-5: Implications for viral infection-associated glomerulonephritis.
Flür K; Allam R; Zecher D; Kulkarni OP; Lichtnekert J; Schwarz M; Beutler B; Vielhauer V; Anders HJ
Am J Pathol; 2009 Nov; 175(5):2014-22. PubMed ID: 19850889
[TBL] [Abstract][Full Text] [Related]
5. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H
Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206
[TBL] [Abstract][Full Text] [Related]
6. Activation of toll-like receptor signaling pathway for protection against influenza virus infection.
Wong JP; Christopher ME; Viswanathan S; Karpoff N; Dai X; Das D; Sun LQ; Wang M; Salazar AM
Vaccine; 2009 May; 27(25-26):3481-3. PubMed ID: 19200852
[TBL] [Abstract][Full Text] [Related]
7. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
[TBL] [Abstract][Full Text] [Related]
8. Brain tumor immunotherapy with type-1 polarizing strategies.
Okada H
Ann N Y Acad Sci; 2009 Sep; 1174():18-23. PubMed ID: 19769732
[TBL] [Abstract][Full Text] [Related]
9. Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model.
Boukhvalova MS; Sotomayor TB; Point RC; Pletneva LM; Prince GA; Blanco JC
J Interferon Cytokine Res; 2010 Apr; 30(4):229-42. PubMed ID: 20038196
[TBL] [Abstract][Full Text] [Related]
10. Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.
Saxena M; Sabado RL; La Mar M; Mohri H; Salazar AM; Dong H; Correa Da Rosa J; Markowitz M; Bhardwaj N; Miller E
Front Immunol; 2019; 10():725. PubMed ID: 31024557
[No Abstract] [Full Text] [Related]
11. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
[TBL] [Abstract][Full Text] [Related]
12. Poly-IC preconditioning protects against cerebral and renal ischemia-reperfusion injury.
Packard AE; Hedges JC; Bahjat FR; Stevens SL; Conlin MJ; Salazar AM; Stenzel-Poore MP
J Cereb Blood Flow Metab; 2012 Feb; 32(2):242-7. PubMed ID: 22086194
[TBL] [Abstract][Full Text] [Related]
13. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population.
Antonelli LR; Gigliotti Rothfuchs A; Gonçalves R; Roffê E; Cheever AW; Bafica A; Salazar AM; Feng CG; Sher A
J Clin Invest; 2010 May; 120(5):1674-82. PubMed ID: 20389020
[TBL] [Abstract][Full Text] [Related]
14. Novel antiviral therapeutics to control foot-and-mouth disease.
Dias CC; Moraes MP; Weiss M; Diaz-San Segundo F; Perez-Martin E; Salazar AM; de los Santos T; Grubman MJ
J Interferon Cytokine Res; 2012 Oct; 32(10):462-73. PubMed ID: 22924938
[TBL] [Abstract][Full Text] [Related]
15. Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys.
Puri SK; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1996 Jan; 16(1):49-52. PubMed ID: 8640451
[TBL] [Abstract][Full Text] [Related]
16. Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice.
Sultan H; Wu J; Kumai T; Salazar AM; Celis E
Cancer Immunol Immunother; 2018 Jul; 67(7):1091-1103. PubMed ID: 29696308
[TBL] [Abstract][Full Text] [Related]
17. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.
Takaki H; Honda K; Atarashi K; Kobayashi F; Ebihara T; Oshiumi H; Matsumoto M; Shingai M; Seya T
Mol Immunol; 2014 Feb; 57(2):100-10. PubMed ID: 24096085
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys.
Kende M; Paragas J; Salazar AM
Antiviral Res; 2019 Mar; 163():179-184. PubMed ID: 30611774
[TBL] [Abstract][Full Text] [Related]
19. Poly ICLC enhances the antimalarial activity of chloroquine against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
Awasthi A; Mehrotra S; Bhakuni V; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1997 Jul; 17(7):419-23. PubMed ID: 9243375
[TBL] [Abstract][Full Text] [Related]
20. Poly-ICLC, a multi-functional immune modulator for treating cancer.
Sultan H; Salazar AM; Celis E
Semin Immunol; 2020 Jun; 49():101414. PubMed ID: 33011064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
